



Board changes at Antisoma

10 December 2003, London, UK - Antisoma plc, the UK-based biopharmaceutical company specialising in the development of products for the treatment of cancer, today announces the appointment of Birgit S. Norinder as a non-executive Director with immediate effect. Mrs Norinder succeeds Dr James Coombes, who retired from the Antisoma Board at the conclusion of the Annual General Meeting of Shareholders on 9 December 2003.

Mrs Norinder has served as Chairman and CEO of Prolifix Ltd, a biotechnology company focusing on oncology, and currently serves on the Boards of a number of biotechnology companies, including two listed companies, PhotoCure ASA of Norway and Probi AB of Sweden. She was previously a Director of Aracel AB (now MiniDoc AB).

Mrs Norinder is a trained pharmacist and has held senior executive positions in R&D in a number of international pharmaceutical companies, including Pharmacia & Upjohn Corp, where she was Senior Vice President Worldwide Product Development, Glaxo Group Research Ltd, where she was Director of the International Regulatory Affairs Division, and Astra Research Centre AB, where she was Vice President, Infection R&D. She has also held positions at Pfizer Inc and at Parke Davis AB.

With regard to Mrs Norinder's appointment, there are no disclosures required under paragraph 6.F.2 (b)-(g) of the Listing Rules of the U.K. Listing Authority.

Commenting, Barry Price, Chairman of Antisoma, said "Birgit has a wealth of experience from the biotech and pharmaceuticals sector, and will provide valuable insight as we enter the next phase of the Company's development. I would like to thank Jim Coombes sincerely for his valuable contribution to Antisoma over the last six years".

Enquiries:

Glyn Edwards, Chief Executive Officer

Tel: +44 (0)20 8799 8200

Ben Atwell/Sarah Macleod, Financial Dynamics

Tel: +44 (0)20 7831 3113

About Antisoma

Based in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. The Company fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates. Antisoma forms partnerships with pharmaceutical companies to bring its products to market. In November 2002, Antisoma formed a broad strategic alliance with Roche to develop and commercialise products from Antisoma's pipeline. Please visit www.antisoma.com for further information about Antisoma.